Sign In
Buy BBH
$205.55
-2.46 (-1.18%)
At Close: Jul 31, 2026
VettaFi Voices On: The Outlook for 2024
03:08pm, Friday, 08'th Dec 2023
Good morning, VettaFi Voices! We are a week out from the VettaFi 2024 Market Outlook Symposium on December 14, which will feature a range of ETF industry leaders discussing their expectations for diff
Should You Invest in the VanEck Biotech ETF (BBH)?
07:32am, Wednesday, 11'th Oct 2023
The VanEck Biotech ETF (BBH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market.
BBH: Our Favorite Biotech ETF Can Keep Outperforming
03:08am, Wednesday, 13'th Sep 2023
VanEck Biotech ETF has outperformed alternative industry ETFs in recent years through its concentration in large-cap leaders. Biotech companies are benefiting from new artificial intelligence tools se
Time for Gilead Sciences-Heavy ETFs?
03:05pm, Tuesday, 12'th Sep 2023
Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.
Biotech Still Has Disruptive Capabilities
01:01pm, Friday, 18'th Aug 2023
In what feels like an eternity in biotechnology terms, broader baskets of the industry's stocks haven't outperformed the S&P 500 Health Care Index annually since 2020. That streak could end this year,
Should You Invest in the VanEck Biotech ETF (BBH)?
07:47am, Friday, 11'th Aug 2023
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on 12/20/2011.
Is Now the Right Time to Embrace Biotech ETFs?
12:34pm, Wednesday, 12'th Jul 2023
Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.
Biotech ETFs in Focus on Covid Vaccines' Fall Rollout
03:37pm, Thursday, 22'nd Jun 2023
The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.
Should You Invest in the VanEck Biotech ETF (BBH)?
07:30am, Wednesday, 31'st May 2023
Launched on 12/20/2011, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
Bevy of Biotech Bargains in BBH
11:35am, Tuesday, 30'th May 2023
Historically, biotechnology stocks trade at premiums relative to the healthcare and the broader market. That's simply the price of admission investors to pay to access the attractive growth prospects
BBH: A Solid Choice For Biotech Exposure
05:44am, Saturday, 27'th May 2023
There are several choices for investors interested in biotech exposure through an ETF. Data analysis shows that biotech ETF returns are more sensitive to timing than the S&P500 and have higher probabi
VanEck's John Patrick Lee Talks Trends Driving Robotics & IBOT
06:06pm, Thursday, 27'th Apr 2023
Earlier this month, VanEck launched the VanEck Robotics ETF (IBOT), a thematic equity ETF offering exposure to the leading global companies that are driving and benefiting from the growth of the robot
VanEck Launches Robotics ETF
10:01am, Monday, 10'th Apr 2023
VanEck launched the VanEck Robotics ETF (IBOT), a thematic equity ETF offering exposure to the leading global companies that are driving and benefiting from the growth of the robotics industry. The fu
Should You Invest in the VanEck Biotech ETF (BBH)?
07:39am, Monday, 27'th Mar 2023
Sector ETF report for BBH
ETFs in Focus on Sanofi and Regeneron's COPD Drug Data
09:12am, Friday, 24'th Mar 2023
Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.
